-
On November 25, 2024, BrioHealth Solutions, Inc., a wholly-owned U.S. subsidiary of BrioHealth Technologies, announced the completion of the first patient enrollment in the INNOVATE Trial of BrioVAD, a fully magnetically levitated left ventricular assist device (LVAD) developed by BrioHealth Technologies. The milestone was achieved at Emory University Hospital in the United States.
-
From November 13 to 15, 2024, the 30th International Society for Mechanical Circulatory Support (ISMCS 2024) conference was successfully held in Utsunomiya, Japan. BrioHealth Technologies was invited to participate in this international academic gathering for the eighth consecutive year, where the company presented multiple research findings on its core products, the fully magnetically levitated left ventricular assist device, CH-VAD and BrioVAD. The presentations garnered widespread attention and high praise from the international academic community.
-
The 8th European Association of Cardio-Thoracic Surgery (EACTS) Mechanical Circulatory Support (MCS) Summit was successfully held in Prague, Czech Republic from November 7 to 9, 2024. Dr. Chen Chen, founder of BrioHealth Technologies, along with Mr. Karl Nelson, Senior Clinical Operations Vice President, were invited to attend the summit.
-
The 18th European Mechanical Circulatory Support Summit (EUMS), a greatly influential international scientific conference in the field of advanced heart failure, was held in Hannover, Germany, from September 11 to 14, 2024 (local time). At the special session of “Best Outcomes: Post and Future of MCS” held on the third day, Prof. Gong Ming from Beijing Anzhen Hospital, Capital Medical University presented the multi-center study results of CH-VAD in his study report Clinical Outcomes in Patients With a Novel Fully Magnetically Levitated Left Ventricular Assist Device: A multi-center study on the international stage!
-
The 18th European Mechanical Circulatory Support Summit (EUMS) was successfully held from September 11th to 14th in Hannover, Germany. Dr. Chen Chen, founder of CH Biomedical, along with Mr. Karl Nelson, Sr. Clinical Operation VP, were invited to this prestigious event.
-
Recently, the landmark INNOVATE clinical trial of CH Biomedical’s BrioVAD has been approved for Medicare coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Under this approval, the required medical device, along with its associated routine examinations and services will be reimbursed by Medicare.
